Clinical trials: Non-small Lung Cancer
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Small Cell Lung Carcinoma
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
- Trial name
- ESCAPE (NCT01357395)
- Testing
- Amuvatinib
- Where
- 12 sites in United States, Poland
- Volunteers
- 23 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.
- Trial name
- NCT01449357
- Testing
- zalutumumab
- Sponsor
- Genmab
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease…
- Trial name
- NCT00556712
- Testing
- erlotinib [Tarceva]
- Where
- 133 sites in Australia, Austria and 26 more
- Volunteers
- 889 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Non Small Cell Lung Cancer
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
This is a phase II study to evaluate the toxicity and overall survival of pulsed paclitaxel with concurrent thoracic radiotherapy, and adjuvant gemcitabine and carboplatin in stage IIIA and IIIB non-small cell lung cancer
- Trial name
- NCT00449657
- Testing
- Taxol (paclitaxel), Radiotherapy, Carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Leo W. Jenkins Cancer Center
Carcinoma, Non-Small-Cell Lung
Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer
This is a research study for patients with inoperable lung cancer called non-small cell lung cancer (NSCLC). Currently, the information from a radiological test, computed tomography (CT) scan of the chest, is used to design the…
- Trial name
- NCT00005666
- Testing
- PET scan use in radiotherapy planning
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Lung Non-Squamous Non-Small Cell Carcinoma
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable).
- Trial name
- NCT07229339
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Neoplasms, Quality of Life
Impact on Quality of Life From Multi-modality Lung Cancer
The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2.
- Trial name
- PIONEER (NCT04540757)
- Testing
- Surgery, No surgery
- Where
- 2 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- The Christie NHS Foundation Trust
Breast Cancer
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00014430
- Testing
- trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Carcinoma, Non-Small-Cell Lung
OMEGA, Local Ablative Therapy in Oligometastatic NSCLC
Oligometastatic lung cancer (OM-NSCLC) seems to be associated with a better prognosis than usual Stage IV non-small cell lung cancer when radical local therapy of all metastatic sites is administered but the impact of such an…
- Trial name
- OMEGA (NCT03827577)
- Testing
- Surgical removal of primary and/or of all oligometastases, Non-surgical LAT, Standard medical therapy
- Where
- Italy
- Volunteers
- 195 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Lung Cancer
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery
RATIONALE: Palliative care may be more effective than standard care in improving quality of life and symptoms in patients with lung cancer.
- Trial name
- NCT00823667
- Testing
- educational intervention, medical chart review, questionnaire administration
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University
Lung Cancer, Cancer of Lymph Node
Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
The purpose of this study is to identify the treatment outcomes of surgical resection with sequential adjuvant chemotherapy and radiotherapy in patients with stage IIIA non-small cell lung cancer and N2 disease at only the sub…
- Conditions
- Lung Cancer, Cancer of Lymph Node, Effects of Chemotherapy, Surgery
- Trial name
- NCT02555592
- Testing
- Primary surgical resection with sequential adjuvant therapy
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Pusan National University Hospital
Non-Small Cell Lung Cancer
Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
This retrospective real-world cohort study evaluated whether concomitant long-term beta-blocker exposure during routine clinical care was associated with clinical outcomes in patients with advanced NSCLC who received standard…
- Trial name
- NCT05387512
- Testing
- Anti-PD-1/PD-L1 Therapy (Standard of Care), Beta-blocker (Concomitant Exposure)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital of Nantong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.